Abstract
Immunosuppressive therapy has been shown to induce sustained hematological responses in a subset of patients with myelodysplastic syndromes (MDS). In particular, antithymocyte globulin (ATG), a polyclonal immunoglobulin induces hematological responses in up to 60% of MDS patients. We report herein on the results of a retrospective multicenter study on the use of ATG in the treatment of 96 patients with MDS. Patients were evaluated for duration of response to ATG, as well as survival after administration of ATG. The median age of the cohort was 54.7 years (range: 19–75 years), with a median follow-up of 33.8 months (range: 0.8–133 months). A total of 40 patients (42%) achieved a hematological response, of which 30 patients (75%) had a durable hematological response lasting a median duration of 31.5 months (range: 6–92 months). On multivariate analysis, both low International Prognostic Scoring System (IPSS) and bone marrow (BM) hypocellularity were independent predictive factors for improved response to ATG (IPSS Int-2/high: odds ratio (OR) 0.08, P=0.018 and BM normo/hypercellularity: OR 0.49, P=0.012). In addition, IPSS was the sole predictor of overall survival, with Int-2/high risk patients having a significantly poorer survival outcome (OR 0.08, P<0.01). In conclusion, this study identifies BM hypocellularity and a low IPSS as important factors predicting response to ATG.
Similar content being viewed by others
References
Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D . Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433.
Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA . Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986; 63: 143–147.
Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG . Myelodysplasia-associated autoimmunity: clinical and pathophysiologic concepts. Eur J Clin Invest 2004; 34: 690–700.
Billstrom R, Johansson H, Johansson B, Mitelman F . Immune-mediated complications in patients with myelodysplastic syndromes – clinical and cytogenetic features. Eur J Haematol 1995; 55: 42–48.
Hamblin TJ . Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33: 150–162.
Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ . Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699–705.
Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low-risk’ myelodysplasia. Br J Haematol 2003; 120: 679–684.
Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100: 4427–4432.
Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barrett AJ . Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002; 119: 97–105.
Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ . Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 3639–3645.
Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ . Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998; 102: 1314–1322.
Barrett J, Saunthararajah Y, Molldrem J . Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15–29.
Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004; 18: 460–465.
Yazji S, Giles FJ, Tsimberidou AM, Estey EH, Kantarjian HM, O'Brien SA et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003; 17: 2101–2106.
Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 1570–1574.
Broliden PA, Dahl IM, Hast R, Johansson B, Juvonen E, Kjeldsen L et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006; 91: 667–670.
Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137: 156–163.
Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP . Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657–662.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
Aivado M, Rong A, Stadler M, Germing U, Giagounidis A, Strupp C et al. Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a ‘non-clonal’ pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 2002; 68: 210–216.
Saunthararajah Y, Nakamura R, Wesley R, Wang QJ, Barrett AJ . A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025–3027.
Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005; 106: 841–851.
Martinez-Jaramillo G, Flores-Figueroa E, Sanchez-Valle E, Gutierrez-Espindola G, Gomez-Morales E, Montesinos JJ et al. Comparative analysis of the in vitro proliferation and expansion of hematopoietic progenitors from patients with aplastic anemia and myelodysplasia. Leuk Res 2002; 26: 955–963.
Young NS, Maciejewski J . The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365–1372.
Nakao S, Takami A, Sugimori N, Ueda M, Shiobara S, Matsuda T et al. Response to immunosuppressive therapy and an HLA-DRB1 allele in patients with aplastic anaemia: HLA-DRB1*1501 does not predict response to antithymocyte globulin. Br J Haematol 1996; 92: 155–158.
Nimer SD, Ireland P, Meshkinpour A, Frane M . An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994; 84: 923–927.
Acknowledgements
We are grateful to Nora Donaldson for her statistical advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lim, Z., Killick, S., Germing, U. et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21, 1436–1441 (2007). https://doi.org/10.1038/sj.leu.2404747
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404747
- Springer Nature Limited
Keywords
This article is cited by
-
Outcome of allogeneic hematopoietic stem cell transplantation for hypoplastic myelodysplastic syndrome
International Journal of Hematology (2020)
-
Evolving therapies for lower-risk myelodysplastic syndromes
Annals of Hematology (2020)
-
Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
Leukemia (2019)
-
Early Detection of Myelodysplastic Syndrome/Leukemia-associated Mutations Using NGS Is Critical in Treating Aplastic Anemia
Current Medical Science (2019)
-
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
Current Hematologic Malignancy Reports (2018)